{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:25:04Z","timestamp":1793496304302,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01617-7","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T07:03:36Z","timestamp":1731481416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD\u2013positive AML"],"prefix":"10.1186","volume":"17","author":[{"given":"Jorge","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"6","key":"1617_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/CCO.0000000000000404","volume":"29","author":"RF Schlenk","year":"2017","unstructured":"Schlenk RF, Muller-Tidow C, Benner A, Kieser M. Relapsed\/refractory acute myeloid leukemia: any progress? Curr Opin Oncol. 2017;29(6):467\u201373.","journal-title":"Curr Opin Oncol"},{"key":"1617_CR2","unstructured":"SEER. Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML). https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html. Accessed 13 Jun 2023."},{"issue":"17","key":"1617_CR3","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","volume":"48","author":"O Visser","year":"2012","unstructured":"Visser O, Trama A, Maynadi\u00e9 M, Stiller C, Marcos-Gragera R, De Angelis R, The RARECARE Working Group, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012;48(17):3257\u201366.","journal-title":"Eur J Cancer."},{"issue":"4","key":"1617_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536\u201345.","journal-title":"Br J Haematol"},{"key":"1617_CR5","unstructured":"American Cancer Society. Key statistics for acute myeloid leukemia (AML). https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html. Accessed 7 Jun 2023."},{"issue":"29","key":"1617_CR6","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","volume":"31","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1617_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"issue":"7","key":"1617_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7): e441.","journal-title":"Blood Cancer J"},{"issue":"12","key":"1617_CR9","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"key":"1617_CR10","doi-asserted-by":"publisher","first-page":"10612880","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith C. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020;10:10612880.","journal-title":"Front Oncol."},{"issue":"2","key":"1617_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312\u201322.","journal-title":"Cancer Sci"},{"issue":"4","key":"1617_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1046\/j.1365-2141.2003.04500.x","volume":"122","author":"PD Kottaridis","year":"2003","unstructured":"Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Haematol. 2003;122(4):523\u201338.","journal-title":"Br J Haematol"},{"key":"1617_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","volume":"2013","author":"M Levis","year":"2013","unstructured":"Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematol Am Soc Hematol Educ Program. 2013;2013:220\u20136.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"23","key":"1617_CR14","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1617_CR15","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2012.e8","volume":"6","author":"T Grafone","year":"2012","unstructured":"Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6(1): e8.","journal-title":"Oncol Rev"},{"issue":"6","key":"1617_CR16","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","volume":"34","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O\u2019Brien S, Koller C, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34(6):752\u20136.","journal-title":"Leuk Res"},{"issue":"5","key":"1617_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12185-019-02720-z","volume":"110","author":"M Sakaguchi","year":"2019","unstructured":"Sakaguchi M, Yamaguchi H, Kuboyama M, Najima Y, Usuki K, Ueki T, et al. Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. Int J Hematol. 2019;110(5):566\u201374.","journal-title":"Int J Hematol"},{"key":"1617_CR18","unstructured":"NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Acute Myeloid Leukemia. Version 2.2024\u2014March 22, 2024. https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf. Accessed 16 Oct 2024."},{"issue":"12","key":"1617_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"4","key":"1617_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12185-024-03730-2","volume":"119","author":"Y Maeda","year":"2024","unstructured":"Maeda Y. JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML). Int J Hematol. 2024;119(4):347\u201373.","journal-title":"Int J Hematol."},{"issue":"6","key":"1617_CR21","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105(6):1507\u201316.","journal-title":"Haematologica"},{"key":"1617_CR22","unstructured":"RYDAPT\u00ae (midostaurin) package insert. Novartis Pharmaceuticals Corporation. May 2023. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/rydapt.pdf. Accessed 24 Jan 2024."},{"key":"1617_CR23","unstructured":"RYDAPT\u00ae (midostaurin) summary of product characteristics. Novartis Europharm Limited. May 2023. https:\/\/www.rydapt.com\/globalassets\/rydaptsplashpage4\/docs\/smpc-eu.may2018.pdf. Accessed 24 Jan 2024."},{"issue":"5","key":"1617_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"9","key":"1617_CR25","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","volume":"35","author":"RA Larson","year":"2021","unstructured":"Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer SM, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603\/RATIFY trial. Leukemia. 2021;35(9):2539\u201351.","journal-title":"Leukemia"},{"issue":"5","key":"1617_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","volume":"56","author":"RT Maziarz","year":"2021","unstructured":"Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56(5):1180\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1617_CR27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","volume":"133","author":"RF Schlenk","year":"2019","unstructured":"Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, the German-Austrian AML Study Group, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840\u201351.","journal-title":"Blood."},{"issue":"15 suppl","key":"1617_CR28","doi-asserted-by":"publisher","first-page":"TPS7068","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7068","volume":"37","author":"RM Stone","year":"2019","unstructured":"Stone RM, Wang ES, Goldberg AD, Sweet KL, Fathi AT, Liu H, et al. Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated. AML J Clin Oncol. 2019;37(15 suppl):TPS7068.","journal-title":"AML J Clin Oncol."},{"key":"1617_CR29","unstructured":"XOSPATA\u00ae (gilteritinib) package insert. Astellas Pharma Inc. Jan 2022. https:\/\/astellas.us\/docs\/xospata.pdf. Accessed 24 Jan 2024."},{"key":"1617_CR30","unstructured":"XOSPATA\u00ae (gilteritinib) summary of product characteristics. Astellas Pharma Europe B.V. Sep 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xospata-epar-product-information_en.pdf. Accessed 24 Jan 2024."},{"issue":"18","key":"1617_CR31","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"15","key":"1617_CR32","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766\u201375.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1617_CR33","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","volume":"16","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Serve H, H\u00fcttmann A, Noppeney R, M\u00fcller-Tidow C, Krug U, Study Alliance Leukaemia, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691\u20139.","journal-title":"Lancet Oncol."},{"issue":"26","key":"1617_CR34","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Rollig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993\u20133002.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1617_CR35","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201\u201312.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1617_CR36","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023;10(8):e600\u201311.","journal-title":"Lancet Haematol"},{"issue":"11","key":"1617_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18632\/oncotarget.27489","volume":"11","author":"T Aikawa","year":"2020","unstructured":"Aikawa T, Togashi N, Iwanaga K, Okada H, Nishiya Y, Inoue S, et al. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. Oncotarget. 2020;11(11):943\u201355.","journal-title":"Oncotarget"},{"issue":"23","key":"1617_CR38","doi-asserted-by":"publisher","first-page":"7808","DOI":"10.1021\/jm9007533","volume":"52","author":"Q Chao","year":"2009","unstructured":"Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N\u2019-4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenylurea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem. 2009;52(23):7808\u201316.","journal-title":"J Med Chem"},{"issue":"4","key":"1617_CR39","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1158\/1535-7163.MCT-12-0305","volume":"12","author":"RN Gunawardane","year":"2013","unstructured":"Gunawardane RN, Nepomuceno RR, Rooks AM, Hunt JP, Ricono JM, Belli B, et al. Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells. Mol Cancer Ther. 2013;12(4):438\u201347.","journal-title":"Mol Cancer Ther"},{"key":"1617_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1476-4598-12-19","volume":"12","author":"KM Kampa-Schittenhelm","year":"2013","unstructured":"Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Dohner H, Dohner K, Schittenhelm MM. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer. 2013;12:19.","journal-title":"Mol Cancer."},{"issue":"6","key":"1617_CR41","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/leu.2015.320","volume":"30","author":"GE Nybakken","year":"2016","unstructured":"Nybakken GE, Canaani J, Roy D, Morrissette JD, Watt CD, Shah NP, et al. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia. 2016;30(6):1422\u20135.","journal-title":"Leukemia"},{"issue":"7","key":"1617_CR42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","volume":"115","author":"KW Pratz","year":"2010","unstructured":"Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425\u201332.","journal-title":"Blood"},{"issue":"20","key":"1617_CR43","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","volume":"120","author":"A Sexauer","year":"2012","unstructured":"Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML. Blood. 2012;120(20):4205\u201314.","journal-title":"Blood"},{"issue":"19","key":"1617_CR44","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1182\/blood-2012-06-436675","volume":"120","author":"SJ Taylor","year":"2012","unstructured":"Taylor SJ, Dagger SA, Thien CB, Wikstrom ME, Langdon WY. Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. Blood. 2012;120(19):4049\u201357.","journal-title":"Blood"},{"issue":"4","key":"1617_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121177","volume":"10","author":"JA Zorn","year":"2015","unstructured":"Zorn JA, Wang Q, Fujimura E, Barros T, Kuriyan J. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PLoS ONE. 2015;10(4): e0121177.","journal-title":"PLoS ONE"},{"issue":"7","key":"1617_CR46","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol"},{"issue":"10388","key":"1617_CR47","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, QuANTUM-First Study Group, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383.","journal-title":"Lancet."},{"issue":"6","key":"1617_CR48","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","volume":"16","author":"M Larrosa-Garcia","year":"2017","unstructured":"Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017;16(6):991\u20131001.","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"1617_CR49","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984\u201392.","journal-title":"Blood"},{"issue":"2","key":"1617_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11899-009-0011-8","volume":"4","author":"M Malaise","year":"2009","unstructured":"Malaise M, Steinbach D, Corbacioglu S. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep. 2009;4(2):77\u201382.","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"1617_CR51","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00280-020-04204-y","volume":"87","author":"D Kang","year":"2021","unstructured":"Kang D, Ludwig E, Jaworowicz D, Huang H, Fiedler-Kelly J, Cortes J, et al. Concentration-QTc analysis of quizartinib in patients with relapsed\/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2021;87(4):513\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1617_CR52","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccep.2017.05.007","volume":"9","author":"ET Locati","year":"2017","unstructured":"Locati ET, Bagliani G, Padeletti L. Normal ventricular repolarization and QT interval: ionic background, modifiers, and measurements. Card Electrophysiol Clin. 2017;9(3):487\u2013513.","journal-title":"Card Electrophysiol Clin"},{"key":"1617_CR53","unstructured":"Vaddady P, Smania G, Bergstrand M, Nakayama S, Inoue H, Kurumaddali A, et al. Concentration-QTcF analysis of quizartinib in patients with newly diagnosed (ND) acute myeloid leukemia (AML). ACoP13. 2022;PMX485. https:\/\/www.go-acop.org\/default.asp?abstract=485."},{"key":"1617_CR54","unstructured":"Daiichi Sankyo Inc. Data on file: Investigator Brochure, August 2022; Summary of Clinical Safety, May 2022; Clinical Study Report of study 2689-CL-2004, July 2018; Clinical Study Report of study AC220-002, June 2018."},{"issue":"2","key":"1617_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/cpdd.770","volume":"9","author":"J Li","year":"2020","unstructured":"Li J, Holmes M, Kankam M, Trone D, Mendell J, Gammon G. Effect of food on the pharmacokinetics of quizartinib. Clin Pharmacol Drug Dev. 2020;9(2):277\u201386.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"1617_CR56","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00280-019-03915-1","volume":"84","author":"J Li","year":"2019","unstructured":"Li J, Trone D, Mendell J, O\u2019Donnell P, Cook N. A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics. Cancer Chemother Pharmacol. 2019;84(4):799\u2013807.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"1617_CR57","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/00498254.2016.1217100","volume":"47","author":"M Sanga","year":"2017","unstructured":"Sanga M, James J, Marini J, Gammon G, Hale C, Li J. An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia. Xenobiotica. 2017;47(10):856\u201369.","journal-title":"Xenobiotica"},{"issue":"22","key":"1617_CR58","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1182\/blood.V128.22.4042.4042","volume":"128","author":"MJ Levis","year":"2016","unstructured":"Levis MJ, Cortes JE, Gammon GM, Trone D, Kang D, Li J. Laboratory and clinical investigations to identify the optimal dosing strategy for quizartinib (AC220) monotherapy in FLT3-Itd-positive (+) relapsed\/refractory (R\/R) acute myeloid leukemia (AML). Blood. 2016;128(22):4042.","journal-title":"Blood"},{"issue":"S1","key":"1617_CR59","first-page":"PI-014","volume":"113","author":"H Zahir","year":"2023","unstructured":"Zahir H, Singh N, Bermudez Y, Kamel YM, Said N, Hsu C, et al. Determination of absolute bioavailability of quizartinib using a microtracer. Clin Pharmacol Ther. 2023;113(S1):PI-014.","journal-title":"Clin Pharmacol Ther."},{"issue":"S1","key":"1617_CR60","first-page":"PII-039","volume":"113","author":"H Zahir","year":"2023","unstructured":"Zahir H, Bermudez Y, Kamel YM, Said N, Hsu C, AbuTarif M, et al. Pharmacokinetics of intestinal P-glycoprotein substrate dabigatran etexilate with and without concomitant quizartinib. Clin Pharmacol Ther. 2023;113(S1):PII-039.","journal-title":"Clin Pharmacol Ther."},{"key":"1617_CR61","unstructured":"Zheng M, Okudaira N, Watanabe A, Inoue S, Nishiya Y, Nakayama S, et al. Development of a physiologically based pharmacokinetic (PBPK) model for quizartinib and evaluation of drug-drug interaction (DDI) risk as an inhibitor of UDP-glucuronosyltransferase 1A1 (UGT1A1). ACoP13. 2022;PMX497. https:\/\/www.go-acop.org\/default.asp?abstract=497."},{"issue":"S1","key":"1617_CR62","first-page":"PI-016","volume":"113","author":"H Zahir","year":"2023","unstructured":"Zahir H, Lasseter K, Marbury T, Rondon JC, Bermudez Y, Gammon G, et al. Effect of mild and moderate hepatic impairment on quizartinib pharmacokinetics. Clin Pharmacol Ther. 2023;113(S1):PI-016.","journal-title":"Clin Pharmacol Ther."},{"issue":"16","key":"1617_CR63","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-1998","volume":"22","author":"TM Cooper","year":"2016","unstructured":"Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, et al. A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in childhood leukemia and lymphoma (TACL) study. Clin Cancer Res. 2016;22(16):4014\u201322.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1617_CR64","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018;132(6):598\u2013607.","journal-title":"Blood"},{"issue":"7397","key":"1617_CR65","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature11016","volume":"485","author":"CC Smith","year":"2012","unstructured":"Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260\u20133.","journal-title":"Nature"},{"issue":"1","key":"1617_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","volume":"130","author":"CC Smith","year":"2017","unstructured":"Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, et al. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017;130(1):48\u201358.","journal-title":"Blood"},{"issue":"14","key":"1617_CR67","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/cncr.28705","volume":"120","author":"Y Alvarado","year":"2014","unstructured":"Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, et al. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014;120(14):2142\u20139.","journal-title":"Cancer"},{"issue":"12","key":"1617_CR68","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","volume":"117","author":"T Sato","year":"2011","unstructured":"Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286\u201393.","journal-title":"Blood"},{"issue":"22","key":"1617_CR69","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","volume":"76","author":"E Traer","year":"2016","unstructured":"Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res. 2016;76(22):6471\u201382.","journal-title":"Cancer Res"},{"issue":"22","key":"1617_CR70","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood.2020007626","volume":"137","author":"LK Schmalbrock","year":"2021","unstructured":"Schmalbrock LK, Dolnik A, Cocciardi S, Str\u00e4ng E, Theis F, Jahn N, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021;137(22):3093\u2013104.","journal-title":"Blood"},{"issue":"2","key":"1617_CR71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","volume":"2","author":"AS Alotaibi","year":"2021","unstructured":"Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, et al. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov. 2021;2(2):125\u201334.","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"1617_CR72","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","volume":"19","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perl AE, D\u00f6hner H, Kantarjian H, Martinelli G, Kovacsovics T, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;19(7):889\u2013903.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1617_CR73","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s12185-019-02709-8","volume":"110","author":"K Usuki","year":"2019","unstructured":"Usuki K, Handa H, Choi I, Yamauchi T, Iida H, Hata T, et al. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. Int J Hematol. 2019;110(6):654\u201364.","journal-title":"Int J Hematol"},{"issue":"2","key":"1617_CR74","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ajh.24959","volume":"93","author":"BM Sandmaier","year":"2018","unstructured":"Sandmaier BM, Khaled S, Oran B, Gammon G, Trone D, Frankfurt O. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2018;93(2):222\u201331.","journal-title":"Am J Hematol"},{"issue":"6","key":"1617_CR75","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12185-019-02727-6","volume":"110","author":"T Takahashi","year":"2019","unstructured":"Takahashi T, Usuki K, Matsue K, Ohno H, Sakura T, Imanaka R, et al. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. Int J Hematol. 2019;110(6):665\u201374.","journal-title":"Int J Hematol"},{"key":"1617_CR76","unstructured":"Daiichi Sankyo. Daiichi Sankyo\u2019s VANFLYTA\u00ae receives approval in Japan for the treatment of relapsed\/refractory FLT3-ITD AML. Daiichi Sankyo. Published 18 Jun 2019. https:\/\/www.daiichisankyo.com\/media\/press_release\/detail\/index_3180.html. Accessed 24 Jan 2024."},{"key":"1617_CR77","unstructured":"Invivoscribe, Inc. The LeukoStrat\u00ae CDx FLT3 Mutation Assay. https:\/\/invivoscribe.com\/products\/companion-diagnostics-cdx\/. Accessed 24 Jan 2024."},{"issue":"23","key":"1617_CR78","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022;139(23):3366\u201375.","journal-title":"Blood"},{"issue":"2","key":"1617_CR79","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ajh.24974","volume":"93","author":"JK Altman","year":"2018","unstructured":"Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213\u201321.","journal-title":"Am J Hematol"},{"key":"1617_CR80","unstructured":"Choi I, Ota S, Ichikawa S, Fujishima N, Iida H, Sugiura I, et al. Phase I result of quizartinib with intensive chemotherapy in newly-diagnosed Japanese AML patients. JSH 2019;abstract 10001. https:\/\/confit.atlas.jp\/guide\/event\/jshem81\/subject\/OS1-10C-4\/date?cryptoId=."},{"key":"1617_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1353","author":"J Qi","year":"2024","unstructured":"Qi J, Choi I, Ota S, Ichikawa S, Fujishima N, Iida H, et al. Safety and pharmacokinetics of quizartinib combination therapy with standard induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia: results from two phase 1 trials in Japan and China. Clin Pharmacol Drug Dev. 2024. https:\/\/doi.org\/10.1002\/cpdd.1353.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1617_CR82","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Oncology Center of Excellence (OCE), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Acute myeloid leukemia: developing drugs and biological products for treatment. August 2020. https:\/\/www.fda.gov\/media\/140821\/download. Accessed Jun 2023."},{"issue":"suppl 1","key":"1617_CR83","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1182\/blood-2023-187286","volume":"140","author":"P Montesinos","year":"2023","unstructured":"Montesinos P, Perl A, Sekeres MA, Liu L, Kamel YM, Imadalou K, et al. Kinetics of complete remission (CR) and CR duration and its impact on overall survival (OS) and event-free survival (EFS) in Quantum-First. Blood. 2023;140(suppl 1):4254.","journal-title":"Blood"},{"key":"1617_CR84","unstructured":"Daiichi Sankyo. VANFLYTA\u00ae first FLT3 inhibitor approved in the U.S. specifically for patients with newly diagnosed FLT3-ITD positive AML. Published 20 Jul 2023. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202307\/20230720_E.pdf. Accessed 24 Jan 2024."},{"key":"1617_CR85","unstructured":"VANFLYTA\u00ae (quizartinib) package insert. Daiichi Sankyo, Inc. July 2023. https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Vanflyta&inline=true. Accessed 24 Jan 2024."},{"key":"1617_CR86","unstructured":"Daiichi Sankyo. VANFLYTA\u00ae first FLT3 inhibitor approved in Japan for patients with newly diagnosed FLT3-ITD positive AML. Published 25 May 2023. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202305\/20230525_E.pdf. Accessed 24 Jan 2024."},{"key":"1617_CR87","unstructured":"Daiichi Sankyo. VANFLYTA\u00ae approved in the EU as the first FLT3 inhibitor specifically for patients with newly diagnosed FLT3-ITD positive AML. Published 9 Nov 2023. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202311\/20231109_E.pdf. . Accessed 24 Jan 2024."},{"key":"1617_CR88","unstructured":"VANFLYTA\u00ae (quizartinib) summary of product characteristics. Daiichi Sankyo, Inc. November 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vanflyta-epar-product-information_en.pdf. Accessed 24 Jan 2024."},{"key":"1617_CR89","unstructured":"VANFLYTA\u00ae (quizartinib) summary of product characteristics. Daiichi Sankyo UK Ltd. March 2024. https:\/\/products.mhra.gov.uk\/substance\/?substance=QUIZARTINIB%20DIHYDROCHLORIDE. Accessed 24 May 2024."},{"key":"1617_CR90","unstructured":"Quizartinib approved to treat adult patients with a type of blood cancer. Press release \u2014 March 11, 2024. https:\/\/www.gov.uk\/government\/news\/quizartinib-approved-to-treat-adult-patients-with-a-type-of-blood-cancer. Accessed 24 May 2024."},{"key":"1617_CR91","unstructured":"Invivoscribe, Inc. Invivoscribe announces FDA approval of the LeukoStrat\u00ae CDx FLT3 Mutation Assay to select patients with FLT3-ITD positive AML for treatment with VANFLYTA\u00ae. Published 21 Jul 2023. https:\/\/invivoscribe.com\/invivoscribe-announces-fda-approval-of-the-leukostrat-cdx-flt3-mutation-assay-to-select-patients-with-flt3-itd-positive-aml-for-treatment-with-vanflyta\/. Accessed 24 Jan 2024."},{"key":"1617_CR92","unstructured":"Invivoscribe, Inc. Invivoscribe announces updated reimbursement for the LeukoStrat CDx FLT3 Mutation Assay\u00ae to select newly diagnosed FLT3-ITD positive AML patients eligible for VANFLYTA\u00ae in Japan. Published 25 May 2023. https:\/\/invivoscribe.com\/invivoscribe-announces-updated-reimbursement-for-the-leukostrat-cdx-flt3-mutation-assay-to-select-newly-diagnosed-flt3-itd-positive-aml-patients-eligible-for-vanflyta-in-japan\/. Accessed 24 Jan 2024."},{"key":"1617_CR93","doi-asserted-by":"crossref","unstructured":"Rohrbach JE, Chang KCN, Karnoub M, Liu L, Kamel YM, S. K-F, et al. Quantum-First (Q-F): clinical bridging study for FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) companion diagnostic development. Blood. 2023;142(suppl 1):4260.","DOI":"10.1182\/blood-2023-186658"},{"issue":"suppl 1","key":"1617_CR94","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1182\/blood-2022-169011","volume":"140","author":"RF Schlenk","year":"2022","unstructured":"Schlenk RF, Montesinos P, Aguilar AR, Vrhovac R, Patkowska E, Kim HJ, et al. Impact of allogeneic hematopoietic cell transplantation in first complete remission in addition to FLT3 inhibition with quizartinib in acute myeloid leukemia with FLT3-internal tandem duplication: results from the Quantum-First trial. Blood. 2022;140(suppl 1):2130\u20132.","journal-title":"Blood"},{"issue":"suppl 1","key":"1617_CR95","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2022-162739","volume":"140","author":"MJ Levis","year":"2022","unstructured":"Levis MJ, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H, et al. Quantum-First trial: FLT3-ITD-specific MRD clearance Is associated with improved overall survival. Blood. 2022;140(suppl 1):546\u20138.","journal-title":"Blood"},{"issue":"suppl 1","key":"1617_CR96","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood-2023-186785","volume":"142","author":"A Perl","year":"2023","unstructured":"Perl A, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H, et al. Quantum-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts). Blood. 2023;142(suppl 1):832.","journal-title":"Blood"},{"key":"1617_CR97","unstructured":"Montesinos P, Patkowska E, Cortes J, Perl AE, Sekeres MA, Dombret H, et al. QuANTUM-First: Efficacy by age in newly diagnosed (nd) patients (pt) With FMS-like tyrosine kinase 3-internal tandem duplication\u2013positive (FLT3-ITD+) acute myeloid leukemia (AML). HemaSphere. 2024;Abstract P589."},{"key":"1617_CR98","unstructured":"Sekeres MA, P. EH, Montesinos P, Patkowska E, Cortes J, Perl AE, et al. QuANTUM-First: efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication\u2013positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy. . HemaSphere. 2024;Abstract S142."},{"issue":"suppl 1","key":"1617_CR99","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1182\/blood-2023-189035","volume":"142","author":"EN Oliva","year":"2023","unstructured":"Oliva EN, Unni S, Cottone F, Vashi R, Li X, Cortes J, et al. Patient-reported outcomes in acute myeloid leukemia patients with FLT3-ITD mutation receiving quizartinib vs. standard chemotherapy: results from the Quantum-First trial. Blood. 2023;142(suppl 1):918.","journal-title":"Blood."},{"key":"1617_CR100","unstructured":"Oliva EN, Unni S, Cottone F, Bauer R, Correges A, Cortes J, et al. QuANTUM-First: patient-reported outcomes (PROs) in newly diagnosed (nd) FLT3-ITD+ acute myeloid leukemia (AML) patients (pts) receiving standard chemotherapy (CTx) plus quizartinib (Q) or placebo (P). Hemasphere. 2024;Abstract P572."},{"issue":"4","key":"1617_CR101","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021;106(4):1034\u201346.","journal-title":"Haematologica"},{"key":"1617_CR102","unstructured":"ClinicalTrials.gov. A phase I\/II study of quizartinib in combination with decitabine and venetoclax for the treatment of patients with acute myeloid leukemia (AML). NCT03661307. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03661307. Accessed Jun 2023."},{"issue":"suppl 1","key":"1617_CR103","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/blood-2023-186699","volume":"142","author":"M Yilmaz","year":"2023","unstructured":"Yilmaz M, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, et al. Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. Blood. 2023;142(suppl 1):158.","journal-title":"Blood"},{"issue":"S3","key":"1617_CR104","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/01.HS9.0000843400.36721.1d","volume":"6","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo C, Kadia T, Borthakur G, et al. Quizartinib with decitabine and venetoclax (triplet) is active in patients with FLT3-ITD mutated acute myeloid leukemia\u2014a phase I\/II study. HemaSphere. 2022;6(S3):28\u20139.","journal-title":"HemaSphere"},{"key":"1617_CR105","unstructured":"ClinicalTrials.gov. A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus venetoclax and quizartinib in newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old ineligible for standard induction chemotherapy. NCT04687761. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04687761. Accessed Jun 2023."},{"key":"1617_CR106","unstructured":"Burgues JMB, Rodr\u00edguez-Veiga R, Cano-Ferri I, Vall-Llovera F, Garcia-Gui\u00f1on A, G\u00f3mez-Espuch J, et al. Updated results of VEN-A-QUI study: a phase 1\u20132 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: azacitidine or low-dose cytarabine with venetoclax and quizartinib. Hemasphere. 2023:abstract S132."},{"issue":"suppl1","key":"1617_CR107","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2023-189676","volume":"142","author":"JMB Burgues","year":"2023","unstructured":"Burgues JMB, Tarazona R, Casado JG, Gordillo JJ, Casas Aviles I, Rodriguez-Veiga R, et al. A high percentage of DNAM-1+ and low percentage of tactile+ NK cells at diagnosis correlate with complete response and survival in AML: a sub-analysis of the Ven-a-Qui Pethema trial. Blood. 2023;142(suppl1):2960.","journal-title":"Blood."},{"key":"1617_CR108","doi-asserted-by":"crossref","unstructured":"Knapper S, Thomas A, King S, Thomas I, Gilkes A, Irwin S, et al. A randomised assessment of the sequential addition of the kinase inhibitor quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial. Hemasphere. 2023;abstract S131.","DOI":"10.1097\/01.HS9.0000967436.08196.70"},{"key":"1617_CR109","unstructured":"ClinicalTrials.gov. A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome. NCT02272478. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02272478. Accessed Jun 2023."},{"issue":"suppl 1","key":"1617_CR110","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2023-186206","volume":"142","author":"HP Erba","year":"2023","unstructured":"Erba HP, Dombert H, Perl A, Mitov T, Liu L, Kamel YM, et al. Quantum-First: safety by treatment phase and by age in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML). Blood. 2023;142(suppl 1):972.","journal-title":"Blood"},{"key":"1617_CR111","unstructured":"ClinicalTrials.gov. Trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type AML. NCT04107727. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04107727. Accessed Jun 2023."},{"key":"1617_CR112","doi-asserted-by":"crossref","unstructured":"Montesinos P, Rodr\u00edguez-Veiga R, Bergua Burgu\u00e9s JM, Algarra L, Botella C, Antonio PSJ, et al. Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild-type AML. HemaSphere. 2023;abstract S130.","DOI":"10.1097\/01.HS9.0000967432.73477.1d"},{"issue":"suppl 1","key":"1617_CR113","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2023-180482","volume":"142","author":"A Mosquera Orgueira","year":"2023","unstructured":"Mosquera Orgueira A, Perez Encinas M, Diaz Arias JA, Rodriguez Veiga R, Burgues JMB, Algarra JL, et al. The FLT3-like gene expression signature predicts response to quizartinib in wild-type FLT3 acute myeloid leukemia: an analysis of the Pethema Quiwi trial. Blood. 2023;142(suppl 1):974.","journal-title":"Blood"},{"key":"1617_CR114","unstructured":"ClinicalTrials.gov. A phase I\/II study of liposomal cytarabine and daunorubicin (CPX-351) in combination with quizartinib in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). NCT04128748. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04128748. Accessed Jun 2023."},{"key":"1617_CR115","unstructured":"ClinicalTrials.gov. A combination of cladribine, idarubicin, cytarabine (CLIA) and quizartinib for the treatment of patients with newly diagnosed or relapsed\/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). NCT04047641. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04047641. Accessed Jun 2023."},{"key":"1617_CR116","unstructured":"ClinicalTrials.gov. Phase I\/II study of azacitidine in combination with quizartinib for patients with myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms with FLT3 or CBL mutations. NCT04493138. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04493138. Accessed Jun 2023."},{"key":"1617_CR117","unstructured":"ClinicalTrials.gov. A phase 1\/2, multicenter, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of quizartinib administered in combination with re-induction chemotherapy, and as a single-agent continuation therapy, in pediatric relapsed\/refractory AML subjects aged 1 month to <18 years (and young adults aged up to 21 years) with FLT3-ITD mutations. NCT03793478. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03793478. Accessed Jun 2023."},{"key":"1617_CR118","unstructured":"CHIP-AML22 master protocol: an open label complex clinical trial in newly diagnosed pediatric de novo AML patients \u2013 a study by the NOPHO-DB-SHIP consortium. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2022-002885-34\/NL. 2022-002885-34. Accessed Jun 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05994690. NCT05994690. Accessed 24 Jan 2024."},{"issue":"suppl 1","key":"1617_CR119","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2023-181792","volume":"142","author":"GJL Kaspers","year":"2023","unstructured":"Kaspers GJL, Wijnen NE, Koedijk JB, Ishimaru S, Benedictus R, Van Opstal EC, et al. Chip-AML22 master protocol: an open-label clinical trial in newly diagnosed pediatric de novo acute myeloid leukemia (AML) patients including a linked phase II trial with quizartinib in FLT3-ITD\/ NPM1wt patients - a study by the NOPHO-DB-SHIP consortium. Blood. 2023;142(suppl 1):1532.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01617-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01617-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01617-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T19:02:23Z","timestamp":1731524543000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01617-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1617"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01617-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JC reports research grants from AbbVie, Daiichi Sankyo, Novartis, Sun Pharma, and Pfizer; consulting fees from AbbVie, Bio-Path, Daiichi Sankyo, Gilead, Forma Therapeutics, Novartis, Pfizer, and Takeda; payment for lectures or speakers bureaus from Novartis, Pfizer, and Takeda; and has stock options with Bio-Path.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}